Introduction
From traditional times, clinical decision-making has relied on biological markers such as HbA1c, lipid profiles, tumor makers, and imaging findings to assess disease control and treatment effectiveness. However, in recent times, it has been observed that medication adherence itself may prove to be the strongest predictor of therapeutic outcomes, often outperforming biological markers in chronic disease management. Despite this, adherence is barely considered as a measurable clinical parameter.
The likelihood of medication adherence to be utilized as a dynamic clinical biomarker, disease trajectory, and risk of adverse outcomes earlier than traditional assessments has enhanced with the development of digital health technologies, which now permit the real-time capture of adherence behaviour.
Why Medication Adherence Matters More Than We Admit
Non-adherence to the prescribed medication therapy is majorly observed, suggesting that approx 30-50% of patients suffering from chronic disease do not follow the medication regimen. Increased hospitalization, disease progression, and mortality in diseases such as diabetes, hypertension, cardiovascular disease, and cancer are associated with poor adherence.
Rather than undetected non-adherence, treatment failure is usually caused due to drug inefficacy, which further leads to unnecessary dose escalation, polypharmacy, or therapy switching.
From Self-Reports to Digital Adherence Data
Some of the traditional methods of measuring adherence are:
- Patient self-reports
- Pill counts
- Pharmacy refill records
However, the benefits of these are limited due to recall bias and poor accuracy.
Recent innovations that help to perform effective monitoring are:
- Smart pill bottles and blister packs
- Ingestible digital pills
- Mobile health applications
- Electronic pharmacy dispensing data
The above mentioned tools provide continuous, time-stamped behavioural data, transforming adherence from an assumption into a measurable variable.
Adherence as a Predictive Clinical Biomarker
According to recent research, significant advancements in clinical biomarkers could occur after changes in adherence patterns. A decline in adherence is linked to worsening disease control and a greater risk of acute events just before the emergence of examination abnormalities in chronic diseases.
From this point of view, adherence data may act as an early warning, helping medical professionals to take action before an individual is admitted to the hospital or the disease worsens. This redefines non-adherence as a clinical risk factor that can be adjusted rather than as an indication of patient failure.
Implications for Pharmacotherapy and Clinical Practice
Pharmacotherapy choices could be profoundly transformed if adherence were treated as a biomarker. Clinicians might address behavioural and contextual impediments to adherence before increasing medication based on test results.
Pharmacists play an important role in evaluating and analyzing adherence data, spot trends in absent doses and carrying out specialized treatments like regimen simplification, counselling, or adherence assistance. This strategy is in accordance with the trend towards customized, preventative, and predictive care.
Ethical and Practical Challenges
Though there are so many benefits, adherence-based monitoring raises moral questions regarding permissions, patient privacy, and possible surveillance. Furthermore, this adherence data may be abused in reimbursement linked to punitive frameworks instead of supportive care models.
Before being widely accepted, digital adherence technologies must also demonstrate clinical validity, equity in access, and connection with current healthcare practices.
Should medication adherence be explicitly incorporated into treatment algorithms as a clinical biomarker if it may predict clinical deterioration before laboratory markers? If so, who should be in charge of analyzing and acting upon this data?